Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by HighTide Therapeutics Inc.

EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies
From HighTide Therapeutics Inc.
Via ACN Newswire
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)
From HighTide Therapeutics Inc.
Via ACN Newswire
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
From HighTide Therapeutics Inc.
Via ACN Newswire
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)
From HighTide Therapeutics Inc.
Via ACN Newswire
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
From HighTide Therapeutics Inc.
Via ACN Newswire
HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology
From HighTide Therapeutics Inc.
Via Business Wire
HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021
From HighTide Therapeutics Inc.
Via Business Wire
HighTide Therapeutics’ HTD1801 Demonstrates Reduced Liver Fat, Improved Glycemic Control and Other Health Measures in Diabetic NASH Patients
From HighTide Therapeutics Inc.
Via Business Wire
HighTide Therapeutics Announces the Presentation of Topline Results of Phase 2 Study of HTD1801 in PSC Patients at the International Liver Congress 2021
From HighTide Therapeutics Inc.
Via Business Wire
HighTide Announces NMPA Approval for HTD1801 Clinical Trial in China
From HighTide Therapeutics Inc.
Via Business Wire
HighTide to Present at the BofA Securities 2021 Health Care Conference
From HighTide Therapeutics Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.